Literature DB >> 20154624

Drug-resistant and extensively drug-resistant tuberculosis in southern Africa.

Martin Peter Grobusch1.   

Abstract

PURPOSE OF REVIEW: Drug-resistant tuberculosis (TB) is of increasing global concern. One of the hardest hit regions is southern Africa. This study focuses on a concise update on recently published developments in the field. RECENT
FINDINGS: There is mounting evidence from high-coprevalence areas that the TB and HIV pandemics must be viewed as an entity and tackled together. In that context, it has become clear that a shift may be required from standard hospital-based models of care towards community-based approaches. Innovative rapid diagnostics to detect TB drug resistance suitable for the use in resource-poor settings and novel drugs effective against drug-resistant Mycobacterium tuberculosis strains are currently developed.
SUMMARY: In order to allow for a maximum impact of novel interventions on the problem of multidrug-resistant and extensively drug-resistant TB, public health systems and existing TB programs must be strengthened significantly.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20154624     DOI: 10.1097/MCP.0b013e3283378680

Source DB:  PubMed          Journal:  Curr Opin Pulm Med        ISSN: 1070-5287            Impact factor:   3.155


  8 in total

Review 1.  TB and HIV in the Central African region: current knowledge and knowledge gaps.

Authors:  S Janssen; M A M Huson; S Bélard; S Stolp; N Kapata; M Bates; M van Vugt; M P Grobusch
Journal:  Infection       Date:  2013-12-06       Impact factor: 3.553

2.  Childhood tuberculosis in Lambaréné, Gabon: tuberculosis control in its infancy?

Authors:  A Flamen; S Bélard; C Kokou; S Janssen; M P Grobusch
Journal:  Infection       Date:  2013-09-14       Impact factor: 3.553

3.  Clinical and laboratory features of tuberculosis within a hospital population in Libreville, Gabon.

Authors:  D U Kombila; J-B Moussavou-Kombila; M P Grobusch; B Lell
Journal:  Infection       Date:  2012-12-13       Impact factor: 3.553

4.  High prevalence of drug resistance amongst HIV-exposed and -infected children in a tuberculosis prevention trial.

Authors:  A C Hesseling; S Kim; S Madhi; S Nachman; H S Schaaf; A Violari; T C Victor; G McSherry; C Mitchell; M F Cotton
Journal:  Int J Tuberc Lung Dis       Date:  2012-02       Impact factor: 2.373

5.  How many sputum culture results do we need to monitor multidrug-resistant-tuberculosis (MDR-TB) patients during treatment?

Authors:  Saskia Janssen; Xavier Padanilam; Rianna Louw; Russel Mahanyele; Gerrit Coetzee; Thomas Hänscheid; Tjalling Leenstra; Martin P Grobusch
Journal:  J Clin Microbiol       Date:  2012-12-05       Impact factor: 5.948

Review 6.  Exploring prospects of novel drugs for tuberculosis.

Authors:  Saskia Janssen; Rajesh Jayachandran; Lulama Khathi; Jakob Zinsstag; Martin P Grobusch; Jean Pieters
Journal:  Drug Des Devel Ther       Date:  2012-09-07       Impact factor: 4.162

7.  Factors influencing specialist care referral of multidrug- and extensively drug-resistant tuberculosis patients in Gauteng/South Africa: a descriptive questionnaire-based study.

Authors:  Deliwe Nkosi; Saskia Janssen; Xavier Padanilam; Rianna Louw; Colin N Menezes; Martin P Grobusch
Journal:  BMC Health Serv Res       Date:  2013-07-09       Impact factor: 2.655

8.  Design, development, drug-likeness, and molecular docking studies of novel piperidin-4-imine derivatives as antitubercular agents.

Authors:  Rajappan Revathi; Ramachandran Venkatesha Perumal; Karkala Sreedhara Ranganath Pai; Govindakarnavar Arunkumar; Dharmarajan Sriram; Suvarna Ganesh Kini
Journal:  Drug Des Devel Ther       Date:  2015-07-21       Impact factor: 4.162

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.